Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Traditional medicine

This article was originally published in The Tan Sheet

Executive Summary

The Traditional Medicines Congress has released a first draft of its detailed model on how to regulate traditional medicines in the U.S., the American Herbal Products Association announces Nov. 29. The 16-page document, "A Proposed Regulatory Model for Traditional Medicines: Guiding Assumptions and Key Components," was published by the nine member organizations of the TM Congress, which formed in spring 2004 to ensure public access to traditional medicinal products. "While some goods that have long been used as traditional medicines fit neatly into [the current legal] framework, the therapeutic uses of these are restricted and many are entirely excluded," AHPA President Michael McGuffin said. "The model proposed here would completely protect the current law while developing a new option that will benefit marketers who want to sell traditional medicines"...

You may also be interested in...

Traditional medicines draft paper

The comment period for a draft paper on a new model for regulating traditional medicines in the U.S. has been extended to June 30, the American Herbal Products Association announces March 29. The draft document, "A Proposed Regulatory Model for Traditional Medicines: Guiding Assumptions & Key Components," was released by the Traditional Medicines Congress in November (1"The Tan Sheet" Dec. 5, 2005, In Brief). Despite the 70 comments already received, an extension was requested by several stakeholders, AHPA says. The group also is clarifying certain "areas of confusion": the TM Congress is not suggesting that herbs marketed as supplements under DSHEA be required to be sold as traditional medicines and is not aiming to influence the practice of medicine under any therapeutic discipline...

Execs On The Move: Promotions Are In The Spotlight At Terumo And MiMedx Group

Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.

COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More

In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts